EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT 55TH ASCO ANNUAL MEETING
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that presentations on a series of abstracts highlighting updates regarding its in-house discovered lenvatinib mesylate (product name: Lenvima®, “lenvatinib”, kinase inhibitor), eribulin mesylate (product name: Halaven®, “eribulin”, halichondrin class microtubule dynamics inhibitor), and MORAb-202 (antibody drug conjugate, ADC) will be given at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, the United States, from May 31 to June 4, 2019. The latest information on H3B-6527 (fibroblast growth factor receptor 4 inhibitor) and H3B-6545 (selective estrogen receptor α covalent antagonist), which were discovered by Eisai’s U.S. oncology precision medicine-focused research and development subsidiary H3 Biomedicine Inc., will also be highlighted in presentations at ASCO.
Major poster presentations at this year’s meeting include highlights of the latest data from an ongoing Phase I clinical study investigating Eisai’s first ADC MORAb-202 in patients with solid tumors in Japan. MORAb-202 is a novel ADC that combines Eisai’s investigational anti-folate receptor α (FRA) antibody farletuzumab with Eisai’s in-house discovered anticancer agent eribulin as the payload.
Eisai positions oncology as a key therapeutic area, and is aiming to discover revolutionary new medicines with the potential to cure cancer. The company will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.
Major Poster Presentations:
| Product | Abstract title and scheduled presentation date and time (local time) |
|---|---|
| Lenvatinib
Abstract No: 6081 |
Influence of tumor size and eastern cooperative oncology group performance status (ECOG PS) at baseline on patient (pt) outcomes in lenvatinib-treated radioiodine-refractory differentiated thyroid cancer (RR-DTC) Poster Presentation | June 1 (Sat), 1:15-4:15 PM |
| Lenvatinib
Abstract No: TPS5607 |
A phase 3 trial evaluating efficacy and safety of lenvatinib in combination with pembrolizumab in patients with advanced endometrial cancer Poster Presentation | June 1 (Sat), 1:15-4:15 PM |
| Lenvatinib
Abstract No: TPS9118 |
Randomized, double-blind, phase 3 trial of first-line pembrolizumab + platinum doublet chemotherapy (chemo) ± lenvatinib in patients (pts) with metastatic nonsquamous non-small-cell lung cancer (NSCLC): LEAP-006 Poster Presentation | June 2 (Sun), 8:00-11:00 AM |
| Lenvatinib
Abstract No: TPS4152 |
Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): phase 3 LEAP-002 study Poster Presentation | June 3 (Mon), 8:00-11:00 AM |
| Lenvatinib
Abstract No: TPS9594 |
Lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with advanced melanoma previously exposed to anti–PD-1/PD-L1 agents: phase 2 LEAP-004 study Poster Presentation | June 3 (Mon), 8:00-11:00 AM |
| Eribulin
Abstract No: 2606 |
Balixafortide (a CXCR4 antagonist) + eribulin in HER2 negative metastatic breast cancer (MBC): survival outcomes of the Phase 1 trial Poster Presentation | June 1 (Sat), 8:00-11:00 AM |
|
MORAb-202
Abstract No: 5544
|
First-in-human (FIH) phase 1 (Ph1) study of MORAb-202 in patients (pts) with advanced folate receptor alpha (FRA)-positive solid tumors Poster Presentation | June 1 (Sat), 1:15-4:45 PM |
|
H3B-6545 Abstract No: 1052 |
Molecular characterization and monitoring of patient ctDNA in phase 1 study of H3B-6545 in ER+ MBC Poster Presentation | June 2 (Sun), 8:00-11:00 AM |
|
H3B-6545 Abstract No: 1059 |
Phase 1 dose escalation of H3B-6545, a first-in-class highly selective ERα Covalent antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC) Poster Presentation | June 2 (Sun), 8:00-11:00 AM |
|
H3B-6527 Abstract No: 4095 |
A phase 1 study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC) patients (pts) Poster Presentation | June 3 (Mon), 8:00-11:00 AM |
|
H3B-6527 Abstract No: 4121 |
H3B-6527 clinical biomarker assay development and characterization of HCC patient samples Poster Presentation | June 3 (Mon), 8:00-11:00 AM |
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
[Notes to editors]
1. About the Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Strategic Collaboration
In March 2018, Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of LENVIMA® (lenvatinib). Under the agreement, the companies will jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A.’s anti-PD-1 therapy KEYTRUDA®(pembrolizumab).
In addition to ongoing clinical studies evaluating the LENVIMA and KEYTRUDA combination across several different tumor types, including renal cell carcinoma, the companies will jointly initiate new clinical studies through the LEAP (LEnvatinib And Pembrolizumab) clinical program, which will evaluate the combination to support 11 potential indications in six types of cancer (endometrial cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck, and urothelial cancer). The LEAP clinical program also includes a new basket trial targeting six additional cancer types (biliary tract cancer, breast cancer, colorectal cancer, gastric cancer, glioblastoma and ovarian cancer). The LENVIMA and KEYTRUDA combination is not approved in any cancer types today.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, N.J., USA.